Akèy › Ensifizyans kadyak › Missouri › Kansas City
Etid klinik pou Ensifizyans kadyak nan Kansas City, MO
25 etid pou Ensifizyans kadyak ap chèche patisipan nan sit nan ak bò kote Kansas City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
ELEVATE-HFpEF Clinical Study
Ap rekrite
- Saint Lukes Mid America Heart Institute, Kansas City
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Ap rekriteFaz 3
- Research Site, Kansas City
- Research Site, Kansas City
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Ap rekriteFaz 3
- Kansas City VA Medical Center, Kansas City
- North Kansas City Hospital, North Kansas City · 2 mi lwen
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Ap rekriteFaz 3
- Kansas City VA Medical Center, Kansas City
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Ap rekriteFaz 3
- Research Site, Kansas City
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Ap rekriteFaz 3
- Saint Luke's Hospital of Kansas City, Kansas City
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Ap rekrite
- Saint Luke's Hospital of Kansas City, Kansas City
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Ap rekriteFaz 3
- Saint Luke's Hospital of Kansas City, Kansas City
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Ap rekriteFaz 3
- Research Site, Kansas City
- Research Site, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Ap rekriteFaz 3
- Kansas City, MO Investigative Site 10002, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Ap rekriteFaz 3
- CON-10002 Kansas City, MO Investigative Site, Kansas City
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
Ap rekriteEtid obsèvasyon
- St. Luke's Hospital of Kansas City, Kansas City
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Ap rekriteFaz 2
- Local Institution - 145, Kansas City
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Ap rekriteEtid obsèvasyon
- Kansas City, Kansas City
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Ap rekriteEtid obsèvasyon
- St. Luke's Mid-America Heart Institute, Kansas City
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Ap rekriteFaz 3
- Tenax Investigational Site, Kansas City
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Ap rekriteFaz 3
- Clinical Research Consultants, JCCT Co, Kansas City
Assessment of CCM in HF With Higher Ejection Fraction
Ap rekrite
- St. Lukes Hospital Kansas City (Mid America Heart Institute), Kansas City
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Ap rekriteFaz 3
- FIN-10002 Kansas City, MO Investigational Site, Kansas City
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Ap rekrite
- St. Lukes/ Mid-American Heart Institute, Kansas City
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Ap rekriteFaz 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Ap rekriteFaz 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Ap rekrite
- St. Luke's Hospital, Kansas City
CCM OPEN HF Registry
Ap rekriteEtid obsèvasyon
- Saint Luke's Hospital Mid America Heart Institute, Kansas City
- Saint Luke's Hospital of Kansas City, Kansas City
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
Ap rekriteEtid obsèvasyon
- Saint Luke's Health System, Kansas City
Etid Ensifizyans kadyak nan lòt vil
- New York City, NY51 etid
- Boston, MA44 etid
- Dallas, TX42 etid
- Houston, TX36 etid
- Cleveland, OH33 etid
- Chicago, IL31 etid
- Philadelphia, PA31 etid
- San Francisco, CA29 etid
- Durham, NC26 etid
- St. Louis, MO26 etid
- Atlanta, GA25 etid
- Cincinnati, OH24 etid
Lòt etid nan Kansas City
- Kansè nan tete34 etid
- Kansè Poumon ki pa ti selil31 etid
- Kansè (tout kalite)21 etid
- Kansè poumon19 etid
- Kansè kolorektal16 etid
- Kansè Metastatik15 etid
- Leksemi mieloïd egi15 etid
- Kansè pwostat14 etid
- Kansè ovè11 etid
- Obèsite11 etid
- Dyabèt Tip 211 etid
- Maladi kadyovaskilè11 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.